Compare First Solar, Inc. (FSLR) vs Novavax Inc (NVAX) Price & Performance

First Solar (FSLR) trades at $220.58, down 0.2% on the day, with a bearish technical signal driven by moving averages. The company shows strong fundamentals with a P/E of 14.46, net income margin of 30.73%, and robust cash flow from operations of $2.06B in 2025. Recent earnings beat in Q1 2026 but missed in prior quarters. Multiple class-action lawsuits filed in July 2026 allege securities fraud, creating near-term legal overhang.

The stock presents a mixed outlook: solid profitability and analyst consensus price target of $275.17 suggest upside, but legal risks and bearish technicals weigh. Investors face tension between strong financial health and potential volatility from litigation outcomes.

Novavax (NVAX) trades at $8.21, down 2.49% amid bearish technical signals and negative cash flow trends. The company shows mixed fundamentals with strong revenue growth to $1.12B in 2025 and three consecutive earnings beats, but faces profitability challenges with negative net income margin and ROE. Recent news highlights shareholder dissent and underperformance versus broader market trends, while analyst consensus remains bullish with a $14 price target representing 70% upside potential.

The outlook balances significant upside potential against substantial execution risks. Positive catalysts include consistent earnings beats and strong analyst support, but concerns persist around cash burn, negative equity, and competitive vaccine market pressures. Investors face volatility from operational challenges despite attractive valuation multiples.